Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comment on: "Effects of a novel mGlu(2/3) receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid" (Lowe S, Dean R, Ackermann B, Jackson K, Natanegara F, Anderson S, Eckstein J, Yuen E, Ayan-Oshodi M, Ho M, McKinzie D, Perry K, Svensson K, Psychopharmacology, 2012).

× No keyword cloud information.

9 in total

1. Comment on "A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia" by Kinon et al.

Authors: Philip Seeman
Journal: J Clin Psychopharmacol Date: 2012-04 Impact factor: 3.153

2. Absence of direct effects on the dopamine D2 receptor by mGluR2/3-selective receptor agonists LY 354,740 and LY 379,268.

Authors: John R Zysk; Dan Widzowski; Linda A Sygowski; Katharine S Knappenberger; Nathan Spear; Charles S Elmore; Peter Dorff; Hongyan Liu; James Doherty; Vijay Chhajlani
Journal: Synapse Date: 2011-01 Impact factor: 2.562

3. Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.

Authors: Stephen Lowe; Robert Dean; Bradley Ackermann; Kimberley Jackson; Fanni Natanegara; Shelby Anderson; James Eckstein; Eunice Yuen; Mosun Ayan-Oshodi; Mary Ho; David McKinzie; Kenneth Perry; Kjell Svensson
Journal: Psychopharmacology (Berl) Date: 2011-08-17 Impact factor: 4.530

4. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.

Authors: Bruce J Kinon; Lu Zhang; Brian A Millen; Olawale O Osuntokun; Judy E Williams; Sara Kollack-Walker; Kimberley Jackson; Ludmila Kryzhanovskaya; Natalia Jarkova
Journal: J Clin Psychopharmacol Date: 2011-06 Impact factor: 3.153

5. Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268.

Authors: Philip Seeman; Carla Caruso; Mercedes Lasaga
Journal: Synapse Date: 2008-02 Impact factor: 2.562

6. Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors.

Authors: Philip Seeman; Hong-Chang Guan
Journal: Synapse Date: 2009-08 Impact factor: 2.562

7. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).

Authors: Matthew J Fell; Kenneth W Perry; Julie F Falcone; Bryan G Johnson; Vanessa N Barth; Karen S Rash; Virginia L Lucaites; Penny G Threlkeld; James A Monn; David L McKinzie; Gerard J Marek; Kjell A Svensson; David L Nelson
Journal: J Pharmacol Exp Ther Date: 2009-09-15 Impact factor: 4.030

8. Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor.

Authors: Philip Seeman; Hong-Chang Guan
Journal: Synapse Date: 2009-10 Impact factor: 2.562

9. Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia.

Authors: Philip Seeman; Hong-Chang Guan
Journal: Synapse Date: 2008-11 Impact factor: 2.562

9 in total